MacroLensNP नेपालीने Sign in Create accountSign up
Free · Life Insurance

RNLI Reliable Nepal Life Insurance Limited

Rs 446.00 -3.00 (-0.67%) as of 2026-11-06 15:00:00
Open
447.20
High
450.00
Low
445.20
Prev. close
449.00
Volume
11,005
Turnover
49.08 lakh
Avg volume (30 d)
17,622
52-week low Rs 402.00
high Rs 520.20 -14.3% from the 52-week high

Reliable Nepal Life Insurance Limited (RNLI) is listed on the Nepal Stock Exchange in the Life Insurance sector. Its share price is Rs 446.00 as of 6 November 2026, 14.3% below its 52-week high of Rs 520.20 and 10.9% above its 52-week low of Rs 402.00. It trades at a P/E of 39.8 on earnings per share of Rs 11.21, cheaper than the Life Insurance sector's median P/E of 56.6.

RNLI paid a dividend in 3 of the last 3 fiscal years we track; the latest was 12.00% cash for FY 2081/2082. Promoters hold 70% of the shares and the public 30%.

Key figures latest report 2082/2083 Q4

Market value
2,318 crore · 23.18 arba
Shares listed
51,968,000
Paid-up capital
519.68 crore · 5.20 arba
EPS (annualised)
Rs 11.21
P/E
39.8
Book value / share
Rs 148.49
P/B
3.00
ROE
7.6%
ROA
2.18%
Dividend yield
2.69%
Net profit (annualised)
58.26 crore
Reserves
–
Total assets
2,676 crore · 26.76 arba
Debt to equity
2.47

Quarter by quarter trailing 12 months at each quarter

QuarterEPSEPS growth (y/y)Net profitRevenueROE
2082/2083 Q4 11.21 +2.2% 58.26 crore 663.42 crore · 6.63 arba 7.6%
2082/2083 Q3 11.06 +4.2% 57.48 crore 235.76 crore · 2.36 arba 7.4%
2082/2083 Q2 11.85 +12.8% 61.57 crore 148.71 crore · 1.49 arba 8.0%
2082/2083 Q1 12.11 +24.3% 62.93 crore 174.47 crore · 1.74 arba 8.1%
2081/2082 Q4 10.97 +33.7% 57.02 crore 143.91 crore · 1.44 arba 7.5%
2081/2082 Q3 10.62 +21.7% 55.19 crore 415.29 crore · 4.15 arba 7.3%
2081/2082 Q2 10.50 +18.1% 54.58 crore 532.50 crore · 5.33 arba 7.4%
2081/2082 Q1 9.74 +6.0% 50.63 crore 440.19 crore · 4.40 arba 6.7%

Dividends

Fiscal yearBonusCashBook close
2081/2082– 12.00% 5 Jan 2026
2080/208112.00% 0.63% 9 Jun 2025
2079/208016.00% 0.84% 29 Jan 2024

Bonus / right shares: Jun 2025 Bonus share 12% · Jan 2024 Right share 1:0.16 at Rs -14

Who owns it

Promoters 70% Public 30%
Public float
15,590,400 shares
Mutual funds hold
4.0% of the float
Promoter lock-in
–

MacroLens analysis of RNLI

More on RNLI on the full desk The rating and verdict, fair value, dump risk and warning signs, the 12-month target, the buy / sell meter with every past signal, cornering and broker activity - the analysis behind every number above. Create an account - 7-day trial

Other Life Insurance companies

CompanyPriceTodayP/EP/BMarket value
NLIC Nepal Life Insurance Co. Ltd. 740.00 +0.14% 150.75.87 7,015 crore · 70.15 arba
LICN Life Insurance Co. Nepal 799.00 +0.26% 108.34.49 4,395 crore · 43.95 arba
NLICL National Life Insurance Co. Lt... 580.00 -0.17% 89.14.54 3,301 crore · 33.01 arba
HLI Himalayan Life Insurance Limit... 303.00 -0.10% 87.13.25 2,770 crore · 27.70 arba
PMLI Prabhu Mahalaxmi Life Insuranc... 429.00 +0.37% 60.63.68 2,277 crore · 22.77 arba
ALICL Asian Life Insurance Co. Limit... 422.20 -0.42% 53.53.51 2,217 crore · 22.17 arba
ILI IME Life Insurance Company Lim... 443.00 +0.07% 37.93.27 2,215 crore · 22.15 arba
CLI Citizen Life Insurance Company... 442.00 +0.34% 56.53.36 2,210 crore · 22.10 arba

Every Life Insurance company 14

Browse all NEPSE stocks by sector →

RNLI: common questions

What is the share price of RNLI today?

RNLI (Reliable Nepal Life Insurance Limited) closed at Rs 446.00 as of 6 November 2026 on NEPSE.

Does RNLI pay dividends?

RNLI paid a dividend in 3 of the last 3 fiscal years we track; the latest was 12.00% cash for FY 2081/2082.

What is the P/E ratio of RNLI?

It trades at a P/E of 39.8 on earnings per share of Rs 11.21, cheaper than the Life Insurance sector's median P/E of 56.6.

Is RNLI a good buy?

This page is not buy or sell advice. MacroLens NP rates every NEPSE company on its fundamentals - RNLI's rating, fair value, dump risk and broker activity are on the desk, free for 7 days.

Prices from NEPSE; figures from the company's quarterly reports; dividends, ownership and news from public filings. Research, not a recommendation to buy or sell - see the risk disclosure.